Anthony Sferruzza
Quest Diagnostics
21 Papers
118 Citations
Anthony Sferruzza is an academic researcher from Quest Diagnostics. The author has contributed to research in topics: Genotype & Point mutation. The author has an hindex of 7, co-authored 21 publications.
Chat about Author
Papers
Natural history of celiac disease autoimmunity in a USA cohort followed since 1974
Carlo Catassi,Debby Kryszak,Bushra N. Bhatti,Craig Sturgeon,Kathy J. Helzlsouer,Sandra Clipp,Daniel Gelfond,Elaine L. Leonard Puppa,Anthony Sferruzza,Alessio Fasano +9 more
TL;DR: The CLUE study demonstrated that this increase in CD prevalence increased 2-fold in the CLUE cohort and 5-fold overall in the US since 1974 was due to an increasing number of subjects that lost the immunological tolerance to gluten in their adulthood.
379
Validation of Hepascore, Compared With Simple Indices of Fibrosis, in Patients With Chronic Hepatitis C Virus Infection in United States
Laren Becker,Wael A. Salameh,Anthony Sferruzza,Ke Zhang,Ro ng Chen,Raza Malik,Richard E. Reitz,Imad Nasser,Nezam H. Afdhal +8 more
TL;DR: Hepascore accurately predicted likelihood of developing fibrosis and could alleviate the need for liver biopsy in a subset of patients and was comparable to results seen in previous studies.
79
Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
Kevin Qu,Qiulu Pan,Xi Zhang,Luis Rodriguez,Ke Zhang,Hai-Rong Li,Albert K Ho,Heather R. Sanders,Anthony Sferruzza,Shih Min Cheng,Diedre Nguyen,Dan Jones,Frederic Waldman +12 more
TL;DR: The findings indicate that the cobas assay may miss many V600 mutations in clinical specimens, and the addition of Sanger sequencing for samples with negative cobas results increased the detection rate to 42.9%.
54
Measurement of von Willebrand factor‐FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA‐based assay in a reference laboratory
Olga Zhukov,Joanna Popov,R. Ramos,C. Vause,Susan Ruden,Anthony Sferruzza,Jeffrey S. Dlott,Mervyn A. Sahud +7 more
TL;DR: This ELISA‐based assay provides accurate measurement of VWF:FVIII binding activity and successfully identifies homozygous VWD2N patients and heterozygous carriers and may help avoid the need for mutation analysis in patients with unexplained low FVIII activity.
23
Performance and Clinical Utility of a Commercial von Willebrand Factor Collagen Binding Assay for Laboratory Diagnosis of von Willebrand Disease
TL;DR: In this paper, the analytical performance of a commercially available collagen-binding assay (CBA) and its usefulness in conjunction with other assays for laboratory diagnosis of Von Willebrand disease (VWD) was evaluated.
15